XERS
Xeris Pharmaceuticals Inc
Halal Rating :
Last Price
$3.19
Last updated:
Market Cap
-
7D Change
-2.74%
1 Year Change
27.6%
Company Overview
Industries
Exchange
Next Earnings Date
Xeris Pharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing ready-to-use injectable and infusible drug formulations. The company's primary business is developing innovative solutions for injectable drugs using its proprietary XeriSol™ and XeriJect™ formulation technologies. Their main products include Gvoke®, a ready-to-use glucagon for the treatment of severe hypoglycemia, and Keveyis®, a treatment for primary periodic paralysis.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $54.27m | $74.95m | - | $7.79m | 0.00% | 10.39% |
| June 30, 2024 | $48.06m | $64.22m | - | $7.96m | 0.00% | 12.40% |
| March 31, 2024 | $40.64m | $64.61m | - | $9.72m | 0.00% | 15.05% |
Company Impact
Help us evaluate Xeris Pharmaceuticals Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.